University of Utah researchers are part of an international team, including Danes and Australians, that have developed the world’s smallest, fully functional version of the insulin hormone based on venom from the predatory cone snail. It’s been almost a hundred years since insulin was discovered, but now with this development a potent, fast-acting insulin, based on animal study observations thus far, could accelerate novel insulin treatments that have the potential to dramatically improve the lives of diabetics.
TrialSite News offers a brief of this finding based on a study recently published in Nature Structural and Molecular Biology.
What is important about this development involving University of Utah (“ U of U”)?
According to Danny Hung-Chieh Chou, PhD, U of U Health assistant professor of biochemistry and study corresponding author, “We now have the capability to create a hybrid version of insulin that works in humans and that also appears to have many of the positive attributes of cone snail insulin.” As this advancement could become the basis for a fast-acting insulin Hung-Chieh Chou notes, “That’s an important step forward in our quest to make diabetes treatment...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).